title: Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
abstract: OBJECTIVE
  Naked DNA vaccines can be manufactured simply and are stable at ambient temperature, but require improved delivery technologies to boost immunogenicity. Here we explore in vivo electroporation for multivalent codon-optimized human papillomavirus (HPV) L1 and L2 DNA vaccination.
  
  
  METHODS
  Balb/c mice were vaccinated three times at two week intervals with a fusion protein comprising L2 residues ∼11-88 of 8 different HPV types (11-88×8) or its DNA expression vector, DNA constructs expressing L1 only or L1+L2 of a single HPV type, or as a mixture of several high-risk HPV types and administered utilizing electroporation, i.m. injection or gene gun. Serum was collected two weeks and 3 months after the last vaccination. Sera from immunized mice were tested for in-vitro neutralization titer, and protective efficacy upon passive transfer to naive mice and vaginal HPV challenge. Heterotypic interactions between L1 proteins of HPV6, HPV16 and HPV18 in 293TT cells were tested by co-precipitation using type-specific monoclonal antibodies.
  
  
  RESULTS
  Electroporation with L2 multimer DNA did not elicit detectable antibody titer, whereas DNA expressing L1 or L1+L2 induced L1-specific, type-restricted neutralizing antibodies, with titers approaching those induced by Gardasil. Co-expression of L2 neither augmented L1-specific responses nor induced L2-specific antibodies. Delivery of HPV L1 DNA via in vivo electroporation produces a stronger antibody response compared to i.m. injection or i.d. ballistic delivery via gene gun. Reduced neutralizing antibody titers were observed for certain types when vaccinating with a mixture of L1 (or L1+L2) vectors of multiple HPV types, likely resulting from heterotypic L1 interactions observed in co-immunoprecipitation studies. High titers were restored by vaccinating with individual constructs at different sites, or partially recovered by co-expression of L2, such that durable protective antibody titers were achieved for each type.
  
  
  CONCLUSIONS
  Multivalent vaccination via in vivo electroporation requires spatial separation of individual type L1 DNA vaccines.
authors.affiliation: Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America.
authors.forename: Kihyuck
authors.initials: K
authors.lastname: Kwak
authors.forename: Rosie
authors.initials: R
authors.lastname: Jiang
authors.forename: Subhashini
authors.initials: S
authors.lastname: Jagu
authors.forename: Joshua W
authors.initials: JW
authors.lastname: Wang
authors.forename: Chenguang
authors.initials: C
authors.lastname: Wang
authors.forename: Neil D
authors.initials: ND
authors.lastname: Christensen
authors.forename: Richard B S
authors.initials: RB
authors.lastname: Roden
mesh_terms: D052685:Alphapapillomavirus / Q000145:classification / Q000235:genetics* / Q000276:immunology*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D000918:Antibody Specificity; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology; D002460:Cell Line; D018274:Electroporation; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D051379:Mice; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
references.pmid: 15734974
references.citation: Virology. 1997 Aug 4;234(2):261-6
references.pmid: 9268157
references.citation: J Pathol. 2012 Dec;228(4):534-43
references.pmid: 22711526
references.citation: Virology. 1996 Oct 15;224(2):477-86
references.pmid: 8874508
references.citation: Nat Immunol. 2010 May;11(5):395-402
references.pmid: 20351692
references.citation: Nat Med. 2007 Jul;13(7):857-61
references.pmid: 17603495
references.citation: Hum Vaccin. 2007 Jul-Aug;3(4):109-15
references.pmid: 17611417
references.citation: PLoS One. 2011;6(8):e23310
references.pmid: 21858066
references.citation: Vaccine. 2001 Dec 12;20(5-6):862-9
references.pmid: 11738751
references.citation: J Virol. 1996 Sep;70(9):5875-83
references.pmid: 8709207
references.citation: J Virol. 2001 May;75(9):4332-42
references.pmid: 11287582
references.citation: Sci Transl Med. 2012 Oct 10;4(155):155ra138
references.pmid: 23052295
references.citation: Cell Host Microbe. 2010 Sep 16;8(3):260-70
references.pmid: 20833377
references.citation: Immunity. 2004 Jul;21(1):107-19
references.pmid: 15345224
references.citation: Int J Cancer. 2004 Aug 20;111(2):278-85
references.pmid: 15197783
references.citation: Virology. 2004 Apr 10;321(2):205-16
references.pmid: 15051381
references.citation: Curr Opin Immunol. 2011 Jun;23(3):421-9
references.pmid: 21530212
references.citation: J Virol. 1994 Nov;68(11):7570-4
references.pmid: 7523700
references.citation: J Virol. 2009 Dec;83(24):12692-701
references.pmid: 19793806
references.citation: J Virol. 1996 May;70(5):3298-301
references.pmid: 8627814
references.citation: Vaccine. 1998 Apr;16(6):613-23
references.pmid: 9569473
references.citation: Vaccine. 2011 Jan 17;29(4):795-803
references.pmid: 21094270
references.citation: Protein Sci. 2009 Jul;18(7):1425-38
references.pmid: 19533761
references.citation: Nature. 2000 Dec 7;408(6813):740-5
references.pmid: 11130078
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4262-7
references.pmid: 10200250
references.citation: Lancet Infect Dis. 2011 Dec;11(12):916-24
references.pmid: 21975270
references.citation: Vaccine. 2009 Mar 4;27(10):1511-22
references.pmid: 19174177
references.citation: J Virol. 2003 Apr;77(8):4818-26
references.pmid: 12663788
references.citation: Vet Pathol. 2001 Mar;38(2):203-15
references.pmid: 11280377
references.citation: J Biol Chem. 2007 Oct 26;282(43):31803-11
references.pmid: 17804402
references.citation: J Infect Dis. 2009 Jul 15;200(2):166-71
references.pmid: 19519255
references.citation: PLoS One. 2013;8(1):e55538
references.pmid: 23383218
references.citation: J Virol. 2009 Aug;83(15):7690-705
references.pmid: 19457985
references.citation: J Virol. 2011 Dec;85(24):13253-9
references.pmid: 21976653
references.citation: Vaccine. 2008 Jan 17;26(3):351-60
references.pmid: 18096279
references.citation: J Virol. 1997 Apr;71(4):2988-95
references.pmid: 9060658
references.citation: J Virol. 1999 Jun;73(6):4972-82
references.pmid: 10233959
references.citation: Virology. 2010 May 25;401(1):70-9
references.pmid: 20206957
references.citation: Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25
references.pmid: 16949997
references.citation: J Virol. 2013 Jan;87(1):464-73
references.pmid: 23097431
references.citation: J Virol. 2007 Dec;81(24):13927-31
references.pmid: 17928339
references.citation: Blood. 2004 Feb 15;103(4):1433-7
references.pmid: 14563635
references.citation: Bioelectrochemistry. 2007 May;70(2):501-7
references.pmid: 17258942
references.citation: J Natl Cancer Inst. 2009 Jun 3;101(11):782-92
references.pmid: 19470949
references.citation: Vaccine. 2004 Jun 23;22(19):2489-93
references.pmid: 15193413
references.citation: J Virol. 1993 Dec;67(12):6929-36
references.pmid: 8230414
references.citation: Vaccine. 2006 May 22;24(21):4490-3
references.pmid: 16140436
references.citation: Vaccine. 2007 Jun 6;25(23):4540-53
references.pmid: 17485151
references.citation: Virology. 2000 May 10;270(2):254-7
references.pmid: 10792983
references.citation: J Infect Dis. 1996 Feb;173(2):314-20
references.pmid: 8568291
references.citation: J Virol. 1999 Nov;73(11):9609-13
references.pmid: 10516071
references.citation: Curr Gene Ther. 2006 Oct;6(5):561-78
references.pmid: 17073602
references.citation: Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4
references.pmid: 1334560
references.citation: Immunol Res. 2008;42(1-3):219-32
references.pmid: 19066740
references.citation: J Gen Virol. 1994 Sep;75 ( Pt 9):2445-9
references.pmid: 8077946
references.citation: J Virol. 2001 Oct;75(19):9201-9
references.pmid: 11533183
references.citation: J Gen Virol. 2011 Jan;92(Pt 1):128-40
references.pmid: 21169215
references.citation: Vaccine. 1999 Aug 20;18(1-2):18-28
references.pmid: 10501231
references.citation: J Infect Dis. 2009 Apr 1;199(7):926-35
references.pmid: 19236279
references.citation: J Virol. 1999 Jul;73(7):6188-90
references.pmid: 10364381
references.citation: Hum Gene Ther. 2009 Nov;20(11):1269-78
references.pmid: 19619001
references.citation: PLoS One. 2012;7(6):e39741
references.pmid: 22761884
references.citation: Vaccine. 2009 Oct 30;27(46):6432-4
references.pmid: 19559114
references.citation: J Mol Biol. 2001 Mar 16;307(1):173-82
references.pmid: 11243812
references.citation: Biochem Biophys Res Commun. 2005 Dec 23;338(3):1490-8
references.pmid: 16271701
references.citation: Virology. 2002 Feb 15;293(2):335-44
references.pmid: 11886254
references.citation: Virology. 1996 Sep 1;223(1):174-84
references.pmid: 8806551
references.citation: Int J Cancer. 2006 Jun 15;118(12):3030-44
references.pmid: 16404738
references.citation: Virology. 2010 Sep 30;405(2):289-99
references.pmid: 20598725
references.citation: J Virol. 1993 Apr;67(4):1936-44
references.pmid: 8383219
references.citation: J Exp Med. 2003 Aug 4;198(3):513-20
references.pmid: 12900525
references.citation: Methods. 2006 Sep;40(1):86-97
references.pmid: 16997717
references.citation: Clin Microbiol Rev. 2003 Jan;16(1):1-17
references.pmid: 12525422
references.citation: PLoS One. 2011;6(5):e19252
references.pmid: 21603651
references.citation: Nature. 2008 Oct 2;455(7213):674-8
references.pmid: 18724357
references.citation: J Pathol. 1999 Sep;189(1):12-9
references.pmid: 10451482
references.citation: Adolesc Med State Art Rev. 2010 Aug;21(2):347-63, x-xi
references.pmid: 21047033
references.citation: J Virol. 2009 Oct;83(19):10085-95
references.pmid: 19640991